The preclinical immune-mediated mechanism data are scientifically interesting but early-stage and not part of the current clinical pipeline. Monitor for any future clinical development plans in pancreatic cancer or combination studies with WP1066, but near-term catalysts remain the MIRACLE AML trial.
Price Chart
Executive Summary
Moleculin Biotech announced new preclinical data at the AACR Pancreatic Cancer Conference showing that the antitumor activity of its lead drug Annamycin in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity, suggesting a potential immune-mediated mechanism. The data are preclinical and Annamycin is not in clinical development for pancreatic cancer; the company's primary focus remains the MIRACLE trial in AML.
Key Facts
- Preclinical data presented at AACR Conference on Pancreatic Cancer (Sept 25-28, 2026) indicate Annamycin's antitumor activity in pancreatic cancer is partially mediated by CD8+ T cell cytotoxicity.
- Annamycin is not currently in clinical development for pancreatic cancer; the lead clinical program remains the MIRACLE trial in relapsed/refractory AML.
- The findings are preclinical and may not be predictive of human results.
- The abstract was published as a supplement to the September 15, 2026 issue of Cancer Research.
Financial Impact
No financial figures disclosed; preclinical data only.
Risk Factors
- Preclinical results may not translate to human efficacy.
- Annamycin is not in clinical development for pancreatic cancer, so no near-term clinical catalyst from this data.
- Company requires significant additional financing with no commitments in place.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-031199 |
| Exhibit: ex_1019593.htm | 0001437749-26-031199 |
| Document: 0001437749-26-031199-index-headers.html | 0001437749-26-031199 |
| Document: 0001437749-26-031199-index.html | 0001437749-26-031199 |
| Document: 0001437749-26-031199.txt | 0001437749-26-031199 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $6.19 | awaiting T+20 | — | $7.09 (+14.46%) |
Oct 16, 2026 10d ago | 8-K | $0.2804 | awaiting T+20 | — | $7.09 (+2426.75%) |
Oct 9, 2026 17d ago | 8-K | $0.4139 | awaiting T+20 | — | $7.09 (+1611.77%) |
Oct 5, 2026 21d ago | 8-K | $0.4766 | awaiting T+20 | — | $7.09 (+1386.57%) |
Sep 29, 2026 27d ago | 8-K | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 29, 2026 27d ago | Press Release | $0.5264 | awaiting T+20 | — | $7.09 (+1245.93%) |
Sep 28, 2026 28d ago | 8-K | $0.5690 $7.09 | ▲ +1145.17% | ▲ +1145.20% | $7.09 (+1145.17%) |
Sep 25, 2026 4w ago | 8-K | $0.6016 $6.50 | ▲ +980.45% | ▲ +981.93% | $7.09 (+1077.69%) |
Sep 23, 2026 4w ago | 8-K | $0.5279 $6.31 | ▲ +1095.30% | ▲ +1094.61% | $7.09 (+1242.11%) |
Sep 18, 2026 5w ago | 8-K | $0.5202 | awaiting T+20 | — | $7.09 (−1261.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers